The invention relates to antibodies against the Platelet Derived Growth Factor Receptor beta (PDGFR β), and the use thereof in diagnostic and/or therapeutic applications. In particular, it provides a (VHH) antibody that specifically binds PDGFR β with an apparent binding affinity of less than 10 nM, preferably less than 5 nM, and which does not activate PDGFR β. Also provided are PDGFR β antibodies and conjugates thereof, and their application in the targeted delivery of a diagnostic agent, a therapeutic agent or a combination thereof to a tissue in a subject, in particular to fibrotic tissue comprising activated myofibroblasts.
展开▼